Regeneron (REGN) jumps 14% after disclosing that its Eylea eye drug generated $24M-25M in sales in the six weeks after November 21, slaying a Q4 anlayst forecast of $5M. Regeneron also predicted that 2012 revenue from the medicine would reach $140M-160M.
Sent to 6,868 people who get email alerts on REGN.
Get email alerts on REGN »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $30.